Our goal is to transparently share knowledge, and in our work we review many scientific publications. Here’s a snapshot of top articles and videos, as well as some introductory material if you are new to the field. Enjoy!
Application of radiolabeled peptides for targeted therapy; 177Lu-DOTA-octreotate emits gamma and beta particle radiation, the peptide molecules bind somatostatin receptors on tumor cells and can be applied for both tumor imaging and radionuclide therapy.
There’s much to see here. We are sharing “hot”, recent publications in the field of theranostics. So, take your time, look around, and learn. We hope you enjoy our library. More to come!
Current Status of 177 Lu-PSMA Targeted Therapies and Where Will We Be In the Near Future
ESMO 2019: Preliminary Results of a Phase I/II Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive mCRPC
Phase I/II Trial of Lutetium-177–PSMA-617 Plus Idronoxil in Metastatic Castration-Resistant Prostate Cancer
Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
¹³¹I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications
Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry
Want to know More about Theranostics?
What are Monoclonal Antibodies?
Thank you for visiting our Library.
Knowledge is important in our business, we strive for the highest level of excellence in our business, service, and competencies. Feel free to reach out if you want more information.